Ionis Pharmaceuticals reported its fourth quarter and full year 2024 financial results, revealing a GAAP EPS of $(0.66), surpassing the estimated $(1.10). The company also achieved sales of $227.00 million, significantly exceeding the forecast of $137.60 million. In related financial disclosures, Charles River Laboratories announced an adjusted EPS of $2.66, beating the expected $2.53, with sales reaching $1.003 billion, above the estimated $983.627 million. Krystal Biotech reported a GAAP EPS of $1.52, which also exceeded the estimate of $1.16, alongside sales of $91.14 million, surpassing the forecast of $90.49 million. Conversely, Karyopharm Therapeutics reported a GAAP EPS of $(0.24), beating the estimate of $(0.26), but its sales of $30.54 million fell short of the expected $34.86 million.